Andrew Bate

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8689633/publications.pdf

Version: 2024-02-01

79 papers	4,261 citations	172207 29 h-index	118652 62 g-index
85 all docs	85 docs citations	85 times ranked	3376 citing authors

#	Article	IF	Citations
1	A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiology and Drug Safety, 2002, 11, 3-10.	0.9	822
2	Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet, The, 2005, 365, 482-487.	6.3	363
3	Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. BMJ: British Medical Journal, 2001, 322, 1207-1209.	2.4	196
4	Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Statistical Methods in Medical Research, 2013, 22, 57-69.	0.7	195
5	A Retrospective Evaluation of a Data Mining Approach to Aid Finding New Adverse Drug Reaction Signals in the WHO International Database. Drug Safety, 2000, 23, 533-542.	1.4	176
6	Temporal pattern discovery in longitudinal electronic patient records. Data Mining and Knowledge Discovery, 2010, 20, 361-387.	2.4	148
7	Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events. Statistics in Medicine, 2006, 25, 3740-3757.	0.8	145
8	A statistical methodology for drugâ€“drug interaction surveillance. Statistics in Medicine, 2008, 27, 3057-3070.	0.8	136
9	A Data Mining Approach for Signal Detection and Analysis. Drug Safety, 2002, 25, 393-397.	1.4	120
10	Duplicate detection in adverse drug reaction surveillance. Data Mining and Knowledge Discovery, 2007, 14, 305-328.	2.4	104
11	Association Between Immune-Related Adverse Events During Antiâ€“PD-1 Therapy and Tumor Mutational Burden. JAMA Oncology, 2019, 5, 1633.	3.4	98
12	Disproportionality methods for pharmacovigilance in longitudinal observational databases. Statistical Methods in Medical Research, 2013, 22, 39-56.	0.7	96
13	Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a crossâ€national descriptive study from the PROTECTâ€EU Project. Pharmacoepidemiology and Drug Safety, 2016, 25, 56-65.	0.9	96
14	Good Signal Detection Practices: Evidence from IMI PROTECT. Drug Safety, 2016, 39, 469-490.	1.4	93
15	Associations Between Venous Thromboembolism andÂAntipsychotics. Drug Safety, 2008, 31, 685-694.	1.4	66
16	An Evaluation of the THIN Database in the OMOP Common Data Model for Active Drug Safety Surveillance. Drug Safety, 2013, 36, 119-134.	1.4	64
17	From association to alertâ€”a revised approach to international signal analysis. Pharmacoepidemiology and Drug Safety, 1999, 8, S15-S25.	0.9	62
18	Bayesian Confidence Propagation Neural Network. Drug Safety, 2007, 30, 623-625.	1.4	58

#	Article	IF	Citations
19	From Big Data to Smart Data for Pharmacovigilance: The Role of Healthcare Databases and Other Emerging Sources. Drug Safety, 2018, 41, 143-149.	1.4	54
20	Largeâ€scale regressionâ€based pattern discovery: The example of screening the WHO global drug safety database. Statistical Analysis and Data Mining, 2010, 3, 197-208.	1.4	53
21	Impact of Stratification on Adverse Drug Reaction Surveillance. Drug Safety, 2008, 31, 1035-1048.	1.4	52
22	A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance. Drug Safety, 2015, 38, 749-765.	1.4	50
23	Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction. British Journal of Clinical Pharmacology, 2009, 68, 427-434.	1.1	48
24	Drugâ€“drug interactions â€“ a preventable patient safety issue?. British Journal of Clinical Pharmacology, 2008, 65, 144-146.	1.1	46
25	Prevalence of antibiotic use: a comparison across various European health care data sources. Pharmacoepidemiology and Drug Safety, 2016, 25, 11-20.	0.9	46
26	Hepatic injury and pancreatitis during treatment with serotonin reuptake inhibitors: data from the World Health Organization (WHO) database of adverse drug reactions. International Clinical Psychopharmacology, 2003, 18, 157-161.	0.9	42
27	Teaching Pharmacovigilance: the WHO-ISoP Core Elements of a Comprehensive Modular Curriculum. Drug Safety, 2014, 37, 743-759.	1.4	39
28	Data Mining in Spontaneous Reports. Basic and Clinical Pharmacology and Toxicology, 2006, 98, 324-330.	1.2	35
29	Temporal pattern discovery for trends and transient effects. , 2008, , .		35
30	Hip/femur fractures associated with the use of benzodiazepines (anxiolytics, hypnotics and related) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 project. Pharmacoepidemiology and Drug Safety, 2016, 25, 66-78.	0.9	34
31	The hope, hype and reality of Big Data for pharmacovigilance. Therapeutic Advances in Drug Safety, 2018, 9, 5-11.	1.0	31
32	Computer-assisted expert case definition in electronic health records. International Journal of Medical Informatics, 2016, 86, 62-70.	1.6	30
33	A BAYESIAN RECURRENT NEURAL NETWORK FOR UNSUPERVISED PATTERN RECOGNITION IN LARGE INCOMPLETE DATA SETS. International Journal of Neural Systems, 2005, 15, 207-222.	3.2	29
34	Choosing Among Common Data Models for Realâ€World Data Analyses Fit for Making Decisions About the Effectiveness of Medical Products. Clinical Pharmacology and Therapeutics, 2020, 107, 827-833.	2.3	29
35	Designing and incorporating a real world data approach to international drug development and use: what the UK offers. Drug Discovery Today, 2016, 21, 400-405.	3.2	28
36	Drug Adverse Event Detection in Health Plan Data Using the Gamma Poisson Shrinker and Comparison to the Tree-based Scan Statistic. Pharmaceutics, 2013, 5, 179-200.	2.0	27

#	Article	IF	Citations
37	Pneumonia following antipsychotic prescriptions in electronic health records: a patient safety concern?. British Journal of General Practice, 2010, 60, e385-e394.	0.7	26
38	Defining â€˜Surveillanceâ€™ in Drug Safety. Drug Safety, 2012, 35, 347-357.	1.4	26
39	Artificial Intelligence, Real-World Automation and the Safety of Medicines. Drug Safety, 2021, 44, 125-132.	1.4	26
40	A hit-miss model for duplicate detection in the WHO drug safety database. , 2005, , .		24
41	Reporting Patterns Indicative of Adverse Drug Interactions. Drug Safety, 2011, 34, 253-266.	1.4	24
42	Hypothesis-free signal detection in healthcare databases: finding its value for pharmacovigilance. Therapeutic Advances in Drug Safety, 2019, 10, 204209861986474.	1.0	21
43	Use of Realâ€World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018â€“2019. Clinical Pharmacology and Therapeutics, 2022, 111, 310-320.	2.3	21
44	Safety surveillance of longitudinal databases: methodological considerations. Pharmacoepidemiology and Drug Safety, 2011, 20, 714-717.	0.9	20
45	Risk of acute liver injury associated with use of antibiotics. Comparative cohort and nested caseâ€“control studies using two primary care databases in Europe. Pharmacoepidemiology and Drug Safety, 2016, 25, 29-38.	0.9	16
46	Time Series Disturbance Detection for Hypothesis-Free Signal Detection in Longitudinal Observational Databases. Drug Safety, 2018, 41, 565-577.	1.4	16
47	Signal Detection for Recently Approved Products: Adapting and Evaluating Self-Controlled Case Series Method Using a US Claims and UK Electronic Medical Records Database. Drug Safety, 2018, 41, 523-536.	1.4	16
48	Artificial Intelligence Based on Machine Learning in Pharmacovigilance: A Scoping Review. Drug Safety, 2022, 45, 477-491.	1.4	16
49	Do FDA label changes work? Assessment of the 2010 class label change for proton pump inhibitors using the Sentinel System's analytic tools. Pharmacoepidemiology and Drug Safety, 2018, 27, 332-339.	0.9	15
50	Terminological Challenges in Safety Surveillance. Drug Safety, 2012, 35, 79-84.	1.4	14
51	Safety of medicines and vaccines â€“ building next generation capability. Trends in Pharmacological Sciences, 2021, 42, 1051-1063.	4.0	14
52	Evidence generation from healthcare databases: recommendations for managing change. Pharmacoepidemiology and Drug Safety, 2016, 25, 749-754.	0.9	13
53	Developing a Crowdsourcing Approach and Tool for Pharmacovigilance Education Material Delivery. Drug Safety, 2017, 40, 191-199.	1.4	13
54	Transparent Reporting on Research Using Unstructured Electronic Health Record Data to Generate â€˜Real Worldâ€™ Evidence of Comparative Effectiveness and Safety. Drug Safety, 2019, 42, 1297-1309.	1.4	13

#	Article	IF	Citations
55	From association to alertâ€”a revised approach to international signal analysis. Pharmacoepidemiology and Drug Safety, 1999, 8, S15-S25.	0.9	12
56	Do caseâ€only designs yield consistent results across design and different databases? A case study of hip fractures and benzodiazepines. Pharmacoepidemiology and Drug Safety, 2016, 25, 79-87.	0.9	12
57	Hepatic injury and pancreatitis during treatment with serotonin reuptake inhibitors. International Clinical Psychopharmacology, 2003, 18, 157-161.	0.9	11
58	Stratification for Spontaneous Report Databases. Drug Safety, 2008, 31, 1145-1147.	1.4	11
59	The authors??? reply. Drug Safety, 2003, 26, 364-366.	1.4	10
60	Data mining in drug safety. Side Effects of Drugs Annual, 2007, 29, xxxiii-xlvi.	0.6	10
61	Safety surveillance of longitudinal databases: results on realâ€world data. Pharmacoepidemiology and Drug Safety, 2012, 21, 673-675.	0.9	10
62	Guidance to reinforce the credibility of health care database studies and ensure their appropriate impact. Pharmacoepidemiology and Drug Safety, 2017, 26, 1013-1017.	0.9	9
63	An Implementation and Visualization of the Tree-Based Scan Statistic for Safety Event Monitoring in Longitudinal Electronic Health Data. Drug Safety, 2019, 42, 727-741.	1.4	9
64	Lessons from metaâ€analyses of randomized clinical trials for analysis of distributed networks of observational databases. Pharmaceutical Statistics, 2019, 18, 65-77.	0.7	9
65	Black Swan Events and Intelligent Automation for Routine Safety Surveillance. Drug Safety, 2022, 45, 419-427.	1.4	9
66	Developing Crowdsourced Training Data Sets for Pharmacovigilance Intelligent Automation. Drug Safety, 2021, 44, 373-382.	1.4	8
67	A Case Study of the Incremental Utility for Disease Identification of Natural Language Processing in Electronic Medical Records. Pharmaceutical Medicine, 2018, 32, 31-37.	1.0	7
68	Artificial Intelligence and Machine Learning for Safe Medicines. Drug Safety, 2022, 45, 403-405.	1.4	7
69	Dose Variations Associated with Formulations of NSAID Prescriptions for Children. Drug Safety, 2011, 34, 307-317.	1.4	5
70	Assessing performance of sequential analysis methods for active drug safety surveillance using observational data. Journal of Biopharmaceutical Statistics, 2018, 28, 668-681.	0.4	3
71	Sudden Cardiac Death in Users of Second-Generation Antipsychotics. Journal of Clinical Psychiatry, 2009, 70, 1725-1726.	1.1	3
72	Engaging Patients via Online Healthcare Fora: Three Pharmacovigilance Use Cases. Frontiers in Pharmacology, 0, 13, .	1.6	3

#	Article	IF	Citations
73	Abacavir and increased risk of myocardial infarction. Lancet, The, 2008, 372, 805.	6.3	2
74	Real World Evidence: Time for a Switch?. Drug Safety, 2018, 41, 1309-1312.	1.4	2
75	The International Society for Pharmacoepidemiology's Comments on the Core Recommendations in the Summary of the Heads of Medicines Agencies (HMA) â€•EMA Joint Big Data Task Force. Pharmacoepidemiology and Drug Safety, 2019, 28, 1640-1641.	0.9	2
76	Measuring the Effectiveness of Real-World Evidence to Ensure Appropriate Impact. Value in Health, 2021, 24, 1241-1244.	0.1	2
77	Bayesian Neural Networks used to Find Adverse Drug Combinations and Drug Related Syndromes. Perspectives in Neural Computing, 2000, , 215-220.	0.1	2
78	A Novel Approach to Visualize Risk Minimization Effectiveness: Peeping at the 2012 UK Proton Pump Inhibitor Label Change Using a Rapid Cycle Analysis Tool. Drug Safety, 2019, 42, 1365-1376.	1.4	0
79	Data Mining in Pharmacovigilance: A View from the Uppsala Monitoring Centre. , 0, , 265-275.		0